Report

peptide therapeutics market

Peptide Therapeutics Market by Application (Metabolic, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, Renal, and Others), Drug Type (Generic and Innovative), Type of Manufacturing (In-house and Outsourced), Synthesis Technology (Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology) and Geography – Global Forecast up to 2026

pages Pages: 109
tables Tables: 118
charts Charts: 88
country Regions/Countries: 4 / 10
compaines Companies: 10
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Peptides are naturally happening biological molecules which play an essential role in significant biological activities. Many efforts have been taken in pharmaceutical research and development to evolve new peptides for the treatment of various chronic diseases. Around 7000 naturally active peptides have been discovered in the past few years, which act as hormones, neurotransmitters, ion channel ligands, and growth factors to provide various human physiologies. The growth of the Peptide Therapeutics market is directly related to increasing investments in drug discovery. R&D activities in peptide therapeutics are majorly focused on the evolution of drugs related to oncology and metabolic disorders, infectious diseases, and diabetes. A robust product pipeline in this field is also one of the factors projected to propel market growth soon. Besides the market growth drivers, the market restricting factors are the huge cost incurred in developing drugs and restricted regulatory requirements for drug approval. The Peptide Therapeutics Market is estimated to grow at the rate of 9.67% CAGR by 2026.  

Research Methodology:

The Peptide Therapeutics Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Peptide Therapeutics Market

Peptide Therapeutics Market by Application

  • Metabolic
  • Cardiovascular Disorder
  • Respiratory
  • GIT
  • Anti-infection
  • Pain
  • Dermatology
  • CNS
  • Renal
  • Others

Peptide Therapeutics Market by Drug Type

  • Generic
  • Innovative

Peptide Therapeutics Market by Type of Manufacturing

  • In-house
  • Outsourced

Peptide Therapeutics Market by Synthesis Technology

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Peptide Therapeutics Market by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The cancer segment has held the maximum share in the peptide therapeutics market on the basis of application. Since there is an increasing number of cancer patients, it is eventually increasing the prescription of peptide therapeutics to treat cancer. Moreover, the rising demand for efficient and faster-acting therapeutics further accentuates the growth of the segment.

As per the market by drug type, the innovative peptides segment has a significant share in the peptide therapeutics market. This is due to the high investments by various pharmaceuticals in research and development activities to develop and discover new drugs for the increasing number of chronic diseases worldwide.

Further, the market is based on the type of manufacturing; in this segmentation, the in-house manufacturing segment has a major contribution to the peptide therapeutics market share. Most players are involved in the in-house manufacturing process due to strict regulations and high costs incurred in outsourcing.

According to the synthesis technology, the liquid phase peptide synthesis (LPPS) segment has dominated the peptide therapeutics market share. The dominance is attributed to the swelling demand for pure peptides in the development of effective therapeutics. Moreover, the liquid phase peptide synthesis holds usefulness in the extensive production of peptides for industrial purposes.

In terms of geographical segmentation, North America has a substantial share of the peptide therapeutics market growth. This is due to the growing demand for diagnostics in cancer, cardiovascular and other diseases, and the expanding biotechnology industry contributes to the dominance.

Cancer coupled with cardiovascular diseases is the major cause of death in the developed countries around the world. Traditional cancer treatments lack therapeutic uses because of drug resistance, a dearth of tumor selectivity and solubility, and a requirement to develop new therapeutic agents. Therapeutic peptides are a potential and a new effort to treat various diseases and cancer, which has increased the demand for peptide therapeutics.

The vital players of the peptide therapeutics market are Teva Pharmaceuticals Industries Ltd., Novo Nordisk A/S, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc (GSK), Novartis International AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., and Lonza Inc.

Hence, peptide therapeutics is having various prominent advantages when compared to proteins and antibodies. Peptide therapeutics is crucially used in cancer treatment due to the adverse effects of radiation and chemotherapy.

  • This research provides prominent shifts in market dynamics and segmentation details of the peptide therapeutics market.
  • Historical, present, and future market analysis is depicted in this report as qualitative and quantitative.
  • This research also provides the assessment of market developments and emerging segments, and regional markets of the peptide therapeutics market.
  • Essential strategies, company expansions, mergers, acquisitions, and new product launches of major vendors are included in this research.
  1. Executive Summary
  2. Industry Outlook
    1. Industry Overview
    2. Industry Trends
  3. Market Snapshot
    1. Market Definition
    2. Market Outlook
      1. Porter Five Forces
    3. Related Markets
  4. Market characteristics
    1. Market Overview
    2. Market Segmentation
    3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
    4. DRO - Impact Analysis
  5. Application: Market Size & Analysis
    1. Overview
    2. Metabolic
    3. Cardiovascular Disorder
    4. Respiratory
    5. GIT
    6. Anti-infection
    7. Pain
    8. Dermatology
    9. CNS
    10. Renal
    11. Others
  6. Drug Type: Market Size & Analysis
    1. Overview
    2. Generic
    3. Innovative
  7. Type of Manufacturing: Market Size & Analysis
    1. Overview
    2. In-house
    3. Outsourced
  8. Synthesis Technology: Market Size & Analysis
    1. Overview
    2. Solid Phase Peptide Synthesis (SPPS)
    3. Liquid Phase Peptide Synthesis (LPPS)
    4. Hybrid Technology
  9. Geography: Market Size & Analysis
    1. Overview
    2. North America
    3. Europe
    4. Asia Pacific
    5. Rest of the World
  10. Competitive Landscape
    1. Competitor Comparison Analysis
    2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
  11. Vendor Profiles
    1. Teva Pharmaceuticals Industries Ltd.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    2. Novo Nordisk A/S
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    3. Eli Lilly and Company
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    4. Takeda Pharmaceutical Company Limited
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    5. GlaxoSmithKline plc (GSK)
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    6. Novartis International AG
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    7. Pfizer Inc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    8. Merck & Co. Inc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    9. Lonza Inc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
  12. Analyst Opinion
  13. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
      1. Data Collation and In-house Estimation
      2. Market Triangulation
      3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations

TABLE 1.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 2.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR METABOLIC, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 3.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR CARDIOVASCULAR DISORDER, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 4.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR RESPIRATORY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 5.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR GIT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 6.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR ANTI-INFECTION, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 7.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR PAIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 8.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR DERMATOLOGY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 9.           GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR CNS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 10.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR RENAL, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 11.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 12.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 13.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR GENERIC, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 14.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR INNOVATIVE, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 15.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 16.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR IN-HOUSE, 2020-2026 (USD BILLION)

TABLE 17.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR OUTSOURCED, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 18.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE, SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 19.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR SOLID PHASE PEPTIDE SYNTHESIS (SPPS), BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 20.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR LIQUID PHASE PEPTIDE SYNTHESIS (LPPS), BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 21.         GLOBAL PEPTIDE THERAPEUTICS MARKET VALUE FOR HYBRID TECHNOLOGY, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 22.         NORTH AMERICA PEPTIDE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 23.         NORTH AMERICA PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 24.         NORTH AMERICA PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 25.         NORTH AMERICA PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 26.         NORTH AMERICA PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 27.         U.S PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 28.         U.S PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 29.         U.S PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 30.         U.S PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 31.         CANADA PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 32.         CANADA PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 33.         CANADA PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 34.         CANADA PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 35.         EUROPE PEPTIDE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 36.         EUROPE PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 37.         EUROPE PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 38.         EUROPE PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 39.         EUROPE PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 40.         GERMANY PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 41.         GERMANY PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 42.         GERMANY PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 43.         GERMANY PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 44.         U.K PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 45.         U.K PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 46.         U.K PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 47.         U.K PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 48.         FRANCE PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 49.         FRANCE PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 50.         FRANCE PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 51.         FRANCE PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 52.         ITALY PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 53.         ITALY PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 54.         ITALY PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 55.         ITALY PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 56.         SPAIN PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 57.         SPAIN PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 58.         SPAIN PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 59.         SPAIN PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 60.         ROE PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 61.         ROE PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 62.         ROE PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 63.         ROE PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 64.         ASIA PACIFIC PEPTIDE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 65.         ASIA PACIFIC PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 66.         ASIA PACIFIC PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 67.         ASIA PACIFIC PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 68.         ASIA PACIFIC PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 69.         CHINA PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 70.         CHINA PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 71.         CHINA PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 72.         CHINA PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 73.         INDIA PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 74.         INDIA PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 75.         INDIA PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 76.         INDIA PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 77.         JAPAN PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 78.         JAPAN PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 79.         JAPAN PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 80.         JAPAN PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 81.         REST OF APAC PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 82.         REST OF APAC PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 83.         REST OF APAC PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 84.         REST OF APAC PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 85.         REST OF WORLD PEPTIDE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 86.         REST OF WORLD PEPTIDE THERAPEUTICS MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)

TABLE 87.         REST OF WORLD PEPTIDE THERAPEUTICS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)

TABLE 88.         REST OF WORLD PEPTIDE THERAPEUTICS MARKET VALUE, BY SYNTHESIS TECHNOLOGY, 2020-2026 (USD BILLION)

TABLE 89.         TEVA PHARMACEUTICALS INDUSTRIES LTD: FINANCIALS        

TABLE 90.         TEVA PHARMACEUTICALS INDUSTRIES LTD: PRODUCT AND SERVICES

TABLE 91.         TEVA PHARMACEUTICALS INDUSTRIES LTD: RECENT DEVELOPMENTS 

TABLE 92.         NOVO NORDISK A/S: FINANCIALS       

TABLE 93.         NOVO NORDISK A/S: PRODUCT AND SERVICES           

TABLE 94.         NOVO NORDISK A/S: RECENT DEVELOPMENTS

TABLE 95.         ELI LILLY AND COMPANY: FINANCIALS 

TABLE 96.         ELI LILLY AND COMPANY: PRODUCT AND SERVICES    

TABLE 97.         ELI LILLY AND COMPANY: RECENT DEVELOPMENTS     

TABLE 98.         TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS   

TABLE 99.         TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT AND SERVICES       

TABLE 100.       TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS        

TABLE 101.       GLAXOSMITHKLINE PLC (GSK): FINANCIALS    

TABLE 102.       GLAXOSMITHKLINE PLC (GSK): PRODUCT AND SERVICES        

TABLE 103.       GLAXOSMITHKLINE PLC (GSK): RECENT DEVELOPMENTS         

TABLE 104.       NOVARTIS INTERNATIONAL AG: FINANCIALS   

TABLE 105.       NOVARTIS INTERNATIONAL AG: PRODUCT AND SERVICES      

TABLE 106.       NOVARTIS INTERNATIONAL AG: RECENT DEVELOPMENTS        

TABLE 107.       AMGEN INC: FINANCIALS        

TABLE 108.       AMGEN INC: PRODUCT AND SERVICES

TABLE 109.       AMGEN INC: RECENT DEVELOPMENTS 

TABLE 110.       PFIZER INC: FINANCIALS         

TABLE 111.       PFIZER INC: PRODUCT AND SERVICES 

TABLE 112.       PFIZER INC: RECENT DEVELOPMENTS  

TABLE 113.       MERCK & CO. INC: FINANCIALS           

TABLE 114.       MERCK & CO. INC: PRODUCT AND SERVICES   

TABLE 115.       MERCK & CO. INC: RECENT DEVELOPMENTS    

TABLE 116.       LONZA INC: FINANCIALS         

TABLE 117.       LONZA INC: PRODUCT AND SERVICES 

TABLE 118.       LONZA INC: RECENT DEVELOPMENTS  

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Peptide Therapeutics Market by Application (Metabolic, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, Renal, and Others), Drug Type (Generic and Innovative), Type of Manufacturing (In-house and Outsourced), Synthesis Technology (Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology) and Geography – Global Forecast up to 2026
Interested in this report?
Get your FREE sample now!

Select User License

$

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports